Correlation Between Molson Coors and CRISPR Therapeutics

Can any of the company-specific risk be diversified away by investing in both Molson Coors and CRISPR Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Molson Coors and CRISPR Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Molson Coors Beverage and CRISPR Therapeutics AG, you can compare the effects of market volatilities on Molson Coors and CRISPR Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Molson Coors with a short position of CRISPR Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Molson Coors and CRISPR Therapeutics.

Diversification Opportunities for Molson Coors and CRISPR Therapeutics

-0.5

Correlation Coefficient

Molson Coors  CRISPR Therapeutics

Very good diversification

The 3 months correlation between Molson and CRISPR is -0.5. Overlapping area represents the amount of risk that can be diversified away by holding Molson Coors Beverage and CRISPR Therapeutics AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on CRISPR Therapeutics and Molson Coors is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Molson Coors Beverage are associated (or correlated) with CRISPR Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of CRISPR Therapeutics has no effect on the direction of Molson Coors i.e., Molson Coors and CRISPR Therapeutics go up and down completely randomly.

Pair Corralation between Molson Coors and CRISPR Therapeutics

Assuming the 90 days trading horizon Molson Coors Beverage is expected to under-perform the CRISPR Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Molson Coors Beverage is 3.44 times less risky than CRISPR Therapeutics. The stock trades about -0.17 of its potential returns per unit of risk. The CRISPR Therapeutics AG is currently generating about 0.19 of returns per unit of risk over similar time horizon. If you would invest  2,814  in CRISPR Therapeutics AG on April 20, 2025 and sell it today you would earn a total of  1,694  from holding CRISPR Therapeutics AG or generate 60.2% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Molson Coors Beverage  vs.  CRISPR Therapeutics AG

Molson Coors Beverage

Risk-Adjusted Performance

Very Weak

Over the last 90 days Molson Coors Beverage has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's fundamental indicators remain somewhat strong which may send shares a bit higher in August 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

CRISPR Therapeutics

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in CRISPR Therapeutics AG are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, CRISPR Therapeutics sustained solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Molson Coors and CRISPR Therapeutics

The main advantage of trading using opposite Molson Coors and CRISPR Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Molson Coors position performs unexpectedly, CRISPR Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CRISPR Therapeutics will offset losses from the drop in CRISPR Therapeutics' long position.

The idea behind Molson Coors Beverage and CRISPR Therapeutics AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stocks Directory module to find actively traded stocks across global markets.